Answers are grounded in this paper and cite their sources.
Multicenter retrospective study shows efgartigimod effectively treats juvenile myasthenia gravis, indicating promising therapeutic potential.
Our study suggests efgartigimod is an effective therapeutic option for JMG, with favorable efficacy and safety profiles. Further studies are necessary to validate the efficacy and safety of efgartigimod in the pediatric population.
No takes yet. Share an insight, caveat, or question.
Lin et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: